炎症性肠病患者感染SARS-CoV-2风险未显著增加:全美退伍军人事务部队列研究
该研究基于美国退伍军人事务部医疗系统2020年1月至6月的全国性回顾性队列,按年龄、性别、种族、地点和合并症为每例炎症性肠病(IBD)患者匹配2例非IBD患者。结果显示,IBD患者与非IBD患者的SARS-CoV-2感染发生率分别为0.23%与0.20%(P=0.29),无显著差异。
要点
- IBD患者SARS-CoV-2感染率为0.23%,非IBD患者为0.20%。
- 两组感染风险无统计学显著差异(P=0.29)。
- 研究基于美国退伍军人事务部全国队列,匹配了年龄、性别、种族、地点和合并症。
核心结论
- 与无IBD患者相比,IBD患者发生SARS-CoV-2感染的风险未显著增加。
研究设计与样本
- 美国退伍军人事务部医疗系统全国性回顾性队列研究,纳入2020年1月1日至2020年6月30日数据。
- 每例IBD患者按年龄、性别、种族、地点和合并症匹配2例非IBD患者。
主要发现
- 38,378例IBD患者中87例(0.23%)发生SARS-CoV-2感染。
- 67,433例非IBD患者中132例(0.20%)发生SARS-CoV-2感染。
- 两组感染率比较P=0.29。
临床怎么用
- 对于IBD患者,无需因担忧SARS-CoV-2感染风险显著升高而改变常规管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The clinic course of SARS-CoV-2 among patients with inflammatory bowel disease (IBD) has been extensively studied. However, there is a paucity of data on whether patients with IBD have an increased risk of developing SARS-CoV-2 with compared with patients without IBD. METHODS: We conducted a nationwide retrospective cohort study in the US Veterans' Affairs healthcare system from January 1, 2020, to June 30, 2020. We matched each patient with IBD with 2 patients without IBD on age, sex, race, location, and comorbidities. The outcome of interest was development of SARS-CoV-2. RESULTS: Among 38,378 patients with IBD and 67,433 patients without IBD, 87 (0.23%) and 132 (0.20%) patients developed incident SARS-CoV-2 infection, respectively (P = 0.29). DISCUSSION: Patients with IBD are not at a significantly increased risk of developing SARS-CoV-2 infection when compared with patients without IBD.
引用
- Khan N, Patel D, Xie D, et al. Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study. Am J Gastroenterol. 2021. PMID: 33982951. doi:10.14309/ajg.0000000000001012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。